Radiotherapy + TMZ Is Associated With Improved OS in IDH WT and TERT Promoter–Mutant WHO Grade II/III Gliomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Chemoradiotherapy with temozolomide vs. radiotherapy alone in patients with IDH wild-type and TERT promoter mutation WHO grade II/III gliomas: A prospective randomized study
Radiother Oncol 2022 Feb 01;167(xx)1-6, X Qiu, Y Chen, Z Bao, L Chen, T JiangFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.